Research the HHS federal contracting market for research and development in biotechnology under NAICS 541711. Compare top federal contractors and market share, reported contract obligations and spending trends, funding-office attribution, recent award activity, contract types, competition, and procurement methods, observed contract vehicle usage, and potential recompete research leads.
Federal records show $841.5M in net obligations across 687 awards in Research and Development in Biotechnology at the Department of Health and Human Services from Oct 1, 2021 through Oct 23, 2026. This market accounts for 0.56% of $150.2B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations moved from $203.7M in net deobligations to $294.9M in net obligations. 1 prime contractor accounted for at least 80% of positive obligations in that latest period.
FY27 is year-to-date through Oct 23, 2026; earlier years show complete fiscal-year totals.
| Fiscal year | Net obligations | Contract actions | Coverage |
|---|---|---|---|
| FY2022 | $123.2M | 641 | Complete |
| FY2023 | $541.2M | 416 | Complete |
| FY2024 | $85.9M | 358 | Complete |
| FY2025 | −$203.7M | 183 | Complete |
| FY2026 | $294.9M | 119 | Complete |
Oct 24, 2025–Oct 23, 2026, compared with Oct 24, 2024–Oct 23, 2025.
Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.
See how positive obligations were attributed across funding offices in the 12 months ending Oct 23, 2026.
98.4% of positive obligations were attributed to BARDA - ASPR / DAAPPO / BARDA DCMA. That represents $293.8M, up $502.1M from the preceding 12 months.
Latest 12-month share of positive obligations; the gray segment represents all other reported offices.
USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.
Reported funding office
Latest 12 months
$293.8M
98.4% of positive obligations
Versus preceding 12 months
+$502.1M
23 active prime contractors · 32 awards
Reported obligations moved from $208.3M in net deobligations to $293.8M in net obligations. The office’s share of positive obligations moved from 0% to 98.4%, a change of +98.4 percentage points.
The latest period contains 38 actions across 32 awards and 10 newly active prime contractors. The preceding period contained 23 active prime contractors and 30 awards.
Reported funding office
Latest 12 months
$4.9M
1.6% of positive obligations
Versus preceding 12 months
−$1.2M
4 active prime contractors · 4 awards
Reported obligations decreased 19.1% from $6.0M to $4.9M. The office’s share of positive obligations moved from 97.7% to 1.6%, a change of −96.1 percentage points.
The latest period contains 8 actions across 4 awards and 2 newly active prime contractors. The preceding period contained 3 active prime contractors and 4 awards.
Reported funding office
Latest 12 months
$1K
0% of positive obligations
Versus preceding 12 months
+$347K
1 active prime contractor · 1 award
Reported obligations moved from $346K in net deobligations to $1K in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.
The latest period contains 1 action across 1 award. The preceding period contained 4 active prime contractors and 4 awards.
Reported funding office
Latest 12 months
$0
0% of positive obligations
Versus preceding 12 months
+$6K
0 active prime contractors · 0 awards
Reported obligations moved from $6K in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.
The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 2 awards.
Reported funding office
Latest 12 months
$0
0% of positive obligations
Versus preceding 12 months
+$43K
0 active prime contractors · 0 awards
Reported obligations moved from $43K in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.
The latest period contains 0 actions across 0 awards. The preceding period contained 2 active prime contractors and 2 awards.
Reported funding office
Latest 12 months
$0
0% of positive obligations
Versus preceding 12 months
−$140K
0 active prime contractors · 0 awards
Reported obligations decreased 100.0% from $140K to $0. The office’s share of positive obligations moved from 2.3% to 0%, a change of −2.3 percentage points.
The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 1 award.
Reported funding office
Latest 12 months
−$2K
0% of positive obligations
Versus preceding 12 months
+$544K
1 active prime contractor · 1 award
Reported obligations narrowed from $546K to $2K in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.
The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 2 active prime contractors and 2 awards.
Reported funding office
Latest 12 months
−$448K
0% of positive obligations
Versus preceding 12 months
−$285K
3 active prime contractors · 3 awards
Reported obligations widened from $163K to $448K in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.
The latest period contains 3 actions across 3 awards and 1 newly active prime contractor. The preceding period contained 2 active prime contractors and 10 awards.
Reported funding office
Latest 12 months
−$1.5M
0% of positive obligations
Versus preceding 12 months
−$1.5M
2 active prime contractors · 2 awards
Reported obligations moved from $0 in net obligations to $1.5M in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.
The latest period contains 2 actions across 2 awards and 2 newly active prime contractors. The preceding period contained 0 active prime contractors and 0 awards.
Reported funding office
Latest 12 months
−$1.9M
0% of positive obligations
Versus preceding 12 months
−$1.4M
29 active prime contractors · 48 awards
Reported obligations widened from $530K to $1.9M in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.
The latest period contains 56 actions across 48 awards and 7 newly active prime contractors. The preceding period contained 28 active prime contractors and 55 awards.
From Oct 24, 2025 through Oct 23, 2026, 13 awards had positive obligations totaling $322.2M. Np was the leading reported procedure, accounting for 96.0% of positive obligations. Awards with a reported parent IDV accounted for 1.5%. Reported awards used contract vehicles such as BARDA CRN Animal Model Development and Preclinical Models of Infectious Disease.
Only exact reported parent-PIID matches are shown; missing parent IDs are not inferred.
$2.2M
0.68% of positive obligations · 1 matched award
$2.0M
0.64% of positive obligations · 2 matched awards
Compared with Oct 24, 2024–Oct 23, 2025. Based on 13 current awards and 20 preceding awards with positive net obligations.
Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Definitive Contract(D) | 4 | $317.3M | 98.5% |
| Delivery Order(C) | 9 | $4.9M | 1.5% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| IDC(B) | 9 | $4.9M | 1.5% |
| Not reported | 4 | $317.3M | 98.5% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Multiple Award(M) | 9 | $4.9M | 1.5% |
| Not reported | 4 | $317.3M | 98.5% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Np(NEGOTIATED PROPOSAL/QUOTE) | 3 | $309.2M | 96.0% |
| Br(BASIC RESEARCH) | 1 | $8.1M | 2.5% |
| Subject to Multiple Award Fair Opportunity(MAFO) | 8 | $4.9M | 1.5% |
| Mafo(SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY) | 1 | $1K | 0% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| A(FULL AND OPEN COMPETITION) | 5 | $317.3M | 98.5% |
| Full and Open Competition(A) | 8 | $4.9M | 1.5% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Fair Opportunity Given(FAIR) | 9 | $4.9M | 1.5% |
| Not reported | 4 | $317.3M | 98.5% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Not reported | 13 | $322.2M | 100.0% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| U(COST PLUS FIXED FEE) | 4 | $309.2M | 96.0% |
| S(COST NO FEE) | 1 | $8.1M | 2.5% |
| Cost Plus Fixed Fee(U) | 5 | $2.7M | 0.83% |
| Cost No Fee(S) | 3 | $2.2M | 0.68% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Health R&d Services; Health Care Services; Experimental Development(AN13) | 6 | $290.9M | 90.3% |
| Health R&d Services; Health Care Services; Applied Research(AN12) | 4 | $29.3M | 9.1% |
| Health R&d Services; Health Care Services; Basic Research(AN11) | 3 | $2.0M | 0.64% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Office of Assistant Secretary for Preparedness and Response(7505) | 7 | $314.9M | 97.7% |
| National Institutes of Health(7529) | 6 | $7.3M | 2.3% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| Barda - Aspr / Daappo / Barda Dcma(75A501) | 7 | $314.9M | 97.7% |
| National Institutes of Health Nichd(75N940) | 2 | $5.0M | 1.5% |
| National Institutes of Health Niaid(75N930) | 3 | $2.4M | 0.73% |
| National Institutes of Health Nida(75N950) | 1 | $1K | 0% |
| Reported value | Awards | Positive obligations | Share |
|---|---|---|---|
| HHSO100201500004I(7505) | 1 | $2.2M | 0.68% |
| HHSN272201700040I(7529) | 1 | $1.7M | 0.52% |
| HHSN272201700032I(7529) | 1 | $387K | 0.12% |
| HHSN272201300012I(7529) | 1 | $318K | 0.10% |
| HHSN275201300024I(7529) | 1 | $224K | 0.070% |
| HHSO100201700011I(7505) | 3 | $89K | 0.030% |
| HHSN271201600006I(7529) | 1 | $1K | 0% |
| Not reported | 4 | $317.3M | 98.5% |
$2.2M · 0.68%
2 awards · 2 matched parent PIIDs
Evidence: HHSN272201700032I, HHSN272201700040I
$2.0M · 0.64%
Reported award data linked 3 awards to a specific catalog vehicle.
Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Oct 23, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.
Latest 12-month market share, concentration, and complete prime contractor rankings across the period shown.
Based on $321.2M in positive obligations during the 12 months ending Oct 23, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Oct 24, 2024–Oct 23, 2025.
Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.
Last 12mo obligations
$280.2M
87.2%
Dollar movement
+$611.9M
vs. prior 12 months
Last 12mo awards
2 awards
3 actions
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 2 | 2 |
| Not reported | 0 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
$24.0M
7.5%
Dollar movement
−$56.0M
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 1 | 1 |
| Not reported | 0 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
$8.1M
2.5%
Dollar movement
−$39.4M
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 1 | 1 |
| Not reported | 0 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
$4.7M
1.5%
Dollar movement
−$1.2M
vs. prior 12 months
Last 12mo awards
2 awards
5 actions
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 1 | 1 |
| Not reported | 1 | 0 |
| Reported small business | 2 | 1 |
None reported.
Last 12mo obligations
$1.7M
0.52%
Dollar movement
+$1.7M
vs. prior 12 months
Last 12mo awards
10 awards
13 actions
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 0 | 0 |
| Not reported | 10 | 6 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
$1.6M
0.50%
Dollar movement
+$1.8M
vs. prior 12 months
Last 12mo awards
4 awards
6 actions
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 0 | 0 |
| Not reported | 4 | 7 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
$387K
0.12%
Dollar movement
−$29K
vs. prior 12 months
Last 12mo awards
1 award
2 actions
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 0 | 0 |
| Not reported | 1 | 2 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
$318K
0.10%
Dollar movement
−$721K
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 0 | 0 |
| Not reported | 1 | 2 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
$224K
0.070%
Dollar movement
+$224K
vs. prior 12 months
Last 12mo awards
1 award
2 actions
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 0 | 0 |
| Not reported | 1 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
−$12.5M
0%
Dollar movement
−$12.5M
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 1 | 0 |
| Reported no set-aside | 0 | 0 |
| Not reported | 0 | 0 |
| Reported small business | 1 | 0 |
Last 12mo obligations
−$2.5M
0%
Dollar movement
−$2.5M
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 1 | 0 |
| Not reported | 0 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
−$2.2M
0%
Dollar movement
−$2.1M
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 1 | 1 |
| Not reported | 0 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
−$2.0M
0%
Dollar movement
−$2.0M
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 0 | 0 |
| Not reported | 1 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
−$1.4M
0%
Dollar movement
−$145K
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 1 | 1 |
| Not reported | 0 | 0 |
| Reported small business | 0 | 0 |
None reported.
Last 12mo obligations
−$768K
0%
Dollar movement
−$768K
vs. prior 12 months
Last 12mo awards
1 award
1 action
| Reported award evidence | Latest | Prior |
|---|---|---|
| Reported set-aside | 0 | 0 |
| Reported no set-aside | 1 | 0 |
| Not reported | 0 | 0 |
| Reported small business | 0 | 0 |
None reported.
Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.
EXTEND THE BASE (CLIN 0001) AND OPTION 1 (CLIN 0002) PERIOD OF PERFORMANCE THROUGH 31 MARCH 2027 TO ALLOW COMPLETION OF THE REMAINING EFFORT WITHOUT INCREASING THE CONTRACT VALUE. TRANSFER GOVERNMENT-FURNISHED EQUIPMENT (GFE) FROM CONTRACT HHSO100201
The reported potential end date is Mar 31, 2027. Current award value is 70.0% of reported potential value ($197.5M of $282.2M).
Performance period
96.0%
Current award value as a share of potential value
70.0%
Reported performance starts Jun 17, 2016.
No later potential end date is reported; current and potential end dates are both Mar 31, 2027.
$185.2M is obligated against $197.5M in current reported award value (93.8%).
Reported potential end dates: Dec 31, 2023 → Dec 31, 2025 → Sep 30, 2026 → Mar 31, 2027.
Obligations are compared with current reported award value, not treated as a contract ceiling.
DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)
The reported potential end date is Dec 31, 2026. Current award value is 70.1% of reported potential value ($43.4M of $61.9M).
Performance period
98.2%
Current award value as a share of potential value
70.1%
Reported performance starts Sep 28, 2016.
No later potential end date is reported; current and potential end dates are both Dec 31, 2026.
$43.4M is obligated against $43.4M in current reported award value (100.0%).
Reported potential end dates: May 31, 2023 → Sep 15, 2023 → Dec 31, 2024 → Jan 31, 2025 → Dec 31, 2025 → Dec 31, 2026.
Obligations are compared with current reported award value, not treated as a contract ceiling.
E.O. RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING. DESCOPE MOD IAW WITH RTWS TO REMOVE UNUSED FUNDS FROM MULTIPLE CLINS RESULTING IN A DE-OBLIGATION OF $331,708,160.10 AND A REDUCTION IN TOTAL CONTRACT VALUE OF $331,708,160.10.
$279.6M is obligated on an award with a reported potential end date of September 24, 2027.
Performance period
90.8%
Current award value as a share of potential value
77.6%
Reported performance starts Sep 21, 2017.
No later potential end date is reported; current and potential end dates are both Sep 24, 2027.
$279.6M is obligated against $279.6M in current reported award value (100.0%).
Reported potential end dates: Jun 30, 2026 → Sep 24, 2027.
Obligations are compared with current reported award value, not treated as a contract ceiling.
MERCK - EBOLA ZAIRE VACCINE
$236.3M is obligated on an award with a reported potential end date of September 27, 2027.
Performance period
90.7%
Current award value as a share of potential value
81.1%
Reported performance starts Sep 28, 2017.
No later potential end date is reported; current and potential end dates are both Sep 27, 2027.
$236.3M is obligated against $236.3M in current reported award value (100.0%).
Obligations are compared with current reported award value, not treated as a contract ceiling.
DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT
$66.0M is obligated on an award with a reported potential end date of June 28, 2027.
Performance period
93.2%
Current award value as a share of potential value
94.9%
Reported performance starts Jul 28, 2017.
Current performance is reported through May 28, 2027.
$66.0M is obligated against $66.0M in current reported award value (100.0%).
Reported potential end dates: May 28, 2027 → Jun 28, 2027.
Obligations are compared with current reported award value, not treated as a contract ceiling.
THE PURPOSE OF THIS BILATERAL ADMINISTRATIVE MODIFICATION IS TO CHANGE THE KEY PERSONNEL AND ADD AN ALTERNATE COR. 1. CHANGE ARTICLE G.2. CONTRACTING OFFICER'S REPRESENTATIVE (COR) AND ALTERNATIVE CONTRACTING OFFICER'S REPRESENTATIVE (COR)
$38.9M is obligated on an award with a reported potential end date of September 30, 2027.
Performance period
92.2%
Current award value as a share of potential value
100.0%
Reported performance starts Sep 28, 2015.
No later potential end date is reported; current and potential end dates are both Sep 30, 2027.
$38.9M is obligated against $38.9M in current reported award value (100.0%).
Reported potential end dates: Sep 30, 2025 → Sep 30, 2027.
Obligations are compared with current reported award value, not treated as a contract ceiling.
These are research leads, not confirmed recompetes. USAspending records through Oct 23, 2026; reported dates and values can change through later modifications.
Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.
This action
+$277.8M
BARDA - ASPR / DAAPPO / BARDA DCMA
INMAZEB EBOLA THERAPEUTICS
Why it stands out
One action equaled at least half of the market’s latest 12-month positive obligations.
The $277.8M action represented 86.5% of the market’s positive obligations over the latest 12 months.
This action
−$12.5M
BARDA - ASPR / DAAPPO / BARDA DCMA
AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES
Why it stands out
The award contracted while office-attributed spending grew overall.
The action removed $12.5M while office-attributed spending rose $502.1M.
This action
+$24.0M
BARDA - ASPR / DAAPPO / BARDA DCMA
EO14042 EMERGENT AV7909 ANTHRAX VACCINE
Why it stands out
One action represented 7.5% of the market’s latest 12-month positive obligations.
At $24.0M, the action was large enough to materially affect the latest 12-month market picture.
This action
−$2.2M
BARDA - ASPR / DAAPPO / BARDA DCMA
ADVANCED DEVELOPMENT OF CEFTOBIPROLE
Why it stands out
The award contracted while office-attributed spending grew overall.
The action removed $2.2M while office-attributed spending rose $502.1M.
This action
−$2.5M
BARDA - ASPR / DAAPPO / BARDA DCMA
THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE CANCELLING FUNDS IN THE AMOUNT OF $2,539,496.23 AS FOLLOWS: 1. $1,050,656.17 FROM CLIN 0013 2. $1,488,840.00 FROM CLIN 0014 3. $0.06 FROM CLIN 0012
Why it stands out
The award contracted while office-attributed spending grew overall.
The action removed $2.5M while office-attributed spending rose $502.1M.
This action
−$1.4M
OFC ASST SEC FOR PREPARENESS RES
THE PURPOSE OF MODIFICATION P00014 IS TO DE-OBLIGATE CANCELING FUNDS
Why it stands out
This award recorded a material contraction.
The action removed $1.4M. A deobligation does not by itself show lower requirement demand.
Answers based on reported federal contract data.
In the 12 months through October 23, 2026, REGENERON PHARMACEUTICALS INC, EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC., and HOFFMANN-LA ROCHE INC. were the leading HHS research and development in biotechnology prime contractors by positive obligations.
$280,165,976 in positive obligations
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
$23,983,588 in positive obligations
$8,100,000 in positive obligations
Rankings use reported USAspending award data.
HHS net prime contract obligations for research and development in biotechnology under NAICS 541711 changed from -$203,741,580 in the preceding 12 months to $294,855,403 in the 12 months through October 23, 2026. A percentage change is not stated because the preceding value was not positive or the latest value was negative.
Reported contract actions, not outlays or a forecast.
Recent HHS contract award activity reported in the research and development in biotechnology market included actions for REGENERON PHARMACEUTICALS INC, AVITA MEDICAL AMERICAS, LLC, and EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. during the 12 months through October 23, 2026.
REGENERON PHARMACEUTICALS INC · PIID HHSO100201700016C
Modification P00018 · September 25, 2026 · Action obligation: +$277,818,931
AVITA MEDICAL AMERICAS, LLC · PIID HHSO100201500028C
Deobligation P00017 · February 12, 2026 · Action obligation: -$12,532,518
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. · PIID HHSO100201600030C
Modification P00021 · August 18, 2026 · Action obligation: +$23,983,588
BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL · PIID HHSO100201600002C
Deobligation P00020 · September 23, 2026 · Action obligation: -$2,187,274
NOVARTIS PHARMACEUTICALS CORPORATION · PIID HHSO100201700026C
Deobligation P00013 · July 8, 2026 · Action obligation: -$2,539,496
PFIZER INC · PIID HHSO100201500029C
Deobligation P00014 · May 12, 2026 · Action obligation: -$1,379,309
Action obligations are transaction-level amounts, not current award-level obligations.
From October 24, 2025 through October 23, 2026, HHS reported 13 positive-obligation awards for research and development in biotechnology under NAICS 541711. The leading award type was definitive contract. The leading reported procedure was np.
Percentages use positive obligations as the denominator.
6 HHS research and development in biotechnology awards may warrant recompete research based on reported potential-end dates, including awards held by CERUS CORPORATION, DNAE GROUP HOLDINGS LIMITED, and REGENERON PHARMACEUTICALS INC.
CERUS CORPORATION · PIID HHSO100201600009C
Potential end: March 31, 2027
DNAE GROUP HOLDINGS LIMITED · PIID HHSO100201600017C
Potential end: December 31, 2026
REGENERON PHARMACEUTICALS INC · PIID HHSO100201700020C
Potential end: September 24, 2027
MERCK SHARP & DOHME LLC · PIID HHSO100201700012C
Potential end: September 27, 2027
THE EMMES COMPANY, LLC · PIID HHSN275201700002C
Potential end: June 28, 2027
POLYNOVO BIOMATERIALS PTY LTD · PIID HHSO100201500021C
Potential end: September 30, 2027
Research leads, not confirmed recompetes. Dates may change through later modifications.
Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.
Reported obligations include contract actions from October 1, 2021 through October 23, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.
Review data methodology